See more : Finnair Oyj (FNNNF) Income Statement Analysis – Financial Results
Complete financial analysis of Neurogene Inc. (NGNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurogene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- International Public Partnerships Limited (INPP.L) Income Statement Analysis – Financial Results
- vft (6979.TWO) Income Statement Analysis – Financial Results
- ABEJA, Inc. (5574.T) Income Statement Analysis – Financial Results
- Hayward Holdings, Inc. (HAYW) Income Statement Analysis – Financial Results
- Art Emperor Technology And Culture Co., Ltd. (6650.TWO) Income Statement Analysis – Financial Results
Neurogene Inc. (NGNE)
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.26M | 3.20M | 2.28M | 1.82M | 340.00K | 0.00 | 0.00 | 0.00 | 0.00 | 135.95K | 59.57K | 130.78K | 125.60K |
| Gross Profit | -3.26M | -3.20M | -2.28M | -1.82M | -340.00K | 25.00M | 0.00 | 0.00 | 0.00 | -135.95K | -59.57K | -130.78K | -125.60K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.39M | 47.51M | 42.26M | 24.34M | 6.32M | 32.79M | 36.27M | 28.38M | 15.80M | 17.94M | 7.54M | 5.91M | 8.58M |
| General & Administrative | 11.19M | 9.01M | 8.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.19M | 9.01M | 8.27M | 15.39M | 17.79M | 15.74M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M | 1.73M |
| Other Expenses | -28.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 55.58M | 56.52M | 50.53M | 39.73M | 24.10M | 48.52M | 51.12M | 37.65M | 21.34M | 22.24M | 9.32M | 7.55M | 10.30M |
| Cost & Expenses | 55.58M | 56.52M | 50.53M | 41.55M | 24.44M | 48.52M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M | 10.43M |
| Interest Income | 2.95M | 1.34M | 17.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 10.80K | 19.75K |
| Interest Expense | 12.00K | 2.00K | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 2.25M | 42.92K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.30M | 3.20M | 2.28M | 1.82M | 340.00K | 0.00 | 1.00 | 1.00 | -421.00K | 135.95K | 59.57K | 130.78K | 125.60K |
| EBITDA | -52.29M | -51.99M | -49.59M | -31.46M | -69.10M | -31.58M | -50.18M | -37.00M | -21.76M | -21.65M | -8.63M | -7.54M | -10.54M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -55.58M | -56.52M | -50.53M | -41.55M | -24.44M | -23.52M | -51.12M | -37.65M | -21.34M | -22.38M | -9.38M | -7.68M | -10.43M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -94.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.27M | 1.33M | 17.00K | 8.28M | -45.00M | -8.06M | 936.00K | 643.00K | -520.00K | -1.65M | 641.24K | 9.11K | -232.21K |
| Income Before Tax | -36.32M | -55.19M | -50.52M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M | -10.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.00K | 17.00K | -1.00 | 168.14K | 0.00 | -1.00 | -1.00 | 0.00 | -222.00 | -5.04K | 42.29K | -154.47K |
| Net Income | -36.32M | -55.19M | -50.52M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -8.73M | -7.71M | -10.51M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.87 | -0.77 | -1.05 |
| EPS Diluted | -2.83 | -4.30 | -0.92 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.87 | -0.77 | -1.05 |
| Weighted Avg Shares Out | 12.82M | 12.82M | 55.04M | 51.83M | 27.03M | 23.52M | 23.45M | 18.89M | 12.64M | 8.67M | 10.05M | 10.05M | 10.05M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.82M | 55.04M | 51.83M | 27.03M | 23.52M | 23.45M | 18.89M | 12.64M | 8.67M | 10.05M | 10.05M | 10.05M |
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to...
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Bad news on Monday caused the pharmaceutical company's shares to drop massively in after-hours trading, and they continued to slide through Tuesday. So, what was it that sent shares of Neurogene, a stock that was up 269% year-to-date, plummeting?
Shareholders that Lost Money on Neurogene Inc. (NGNE) Should Contact Levi & Korsinsky About Securities Fraud Investigation - NGNE
NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neurogene Inc. ("Neurogene Inc.") (NASDAQ:NGNE) concerning possible violations of federal securities laws. Neurogene issued a press release on...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company")(NASDAQ:NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial
On Monday, Neurogene Inc. NGNE released interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial of NGN-401 gene therapy for female pediatric patients with Rett syndrome, a rare genetic neurological...
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive interim clinical data in the first four participants in the low-dose cohort of...
Neurogene Announces Oversubscribed $200 Million Private Placement
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has entered into a securities purchase agreement for a private investment in...
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose...
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates. “We are pleased that...
Source: https://incomestatements.info
Category: Stock Reports